Literature DB >> 24459006

Fluconazole associated agranulocytosis and thrombocytopenia.

Yanina Pasikhova1, Steven P Ludlow.   

Abstract

CASE: We describe a second case of fluconazole associated agranulocytosis with thrombocytopenia and recovery upon discontinuation of therapy. The patient began to have changes in white blood cells and platelets within 48 h of administration of fluconazole and began to recover with 48 h of discontinuation. This case highlights that drug-induced blood dyscrasias can occur unexpectedly as a result of treatment with a commonly used drug thought to be "safe".
CONCLUSION: According to Naranjo's algorithm the likelihood that our patient's agranulocytosis and thrombocytopenia occurred as a result of therapy with fluconazole is probable, with a total of six points. We feel that the weight of the overall evidence of this evidence is strong. In particular the temporal relationship of bone marrow suppression to the initiation of fluconazole and the abatement of symptoms that rapidly reversed immediately following discontinuation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24459006     DOI: 10.1007/s11096-014-9914-0

Source DB:  PubMed          Journal:  Int J Clin Pharm


  12 in total

1.  Fluconazole-induced agranulocytosis with eosinophilia.

Authors:  A Wong-Beringer; K Shriner
Journal:  Pharmacotherapy       Date:  2000-04       Impact factor: 4.705

2.  Fluconazole-induced thrombocytopenia.

Authors:  A Agarwal; V Sakhuja; K S Chugh
Journal:  Ann Intern Med       Date:  1990-12-01       Impact factor: 25.391

3.  Vancomycin induced neutropenia.

Authors:  H H Kesarwala; W J Rahill; N Amaram
Journal:  Lancet       Date:  1981-06-27       Impact factor: 79.321

4.  Fluconazole-induced agranulocytosis [.

Authors:  S Chuncharunee; B Sathapatayavongs; P Singhasivanon; V Singhasivanon
Journal:  Therapie       Date:  1994 Nov-Dec       Impact factor: 2.070

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

6.  Suppression of progenitor cell growth by vancomycin following autologous stem cell transplantation.

Authors:  K R Meehan; U N Verma; F Esteva-Lorenzo; A Mazumder
Journal:  Bone Marrow Transplant       Date:  1997-05       Impact factor: 5.483

7.  Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome.

Authors:  A M Sugar; C Saunders
Journal:  Am J Med       Date:  1988-10       Impact factor: 4.965

8.  Agranulocytosis during treatment with fluconazole.

Authors:  H Murakami; H Katahira; T Matsushima; T Sakura; J Tamura; M Sawamura; J Tsuchiya
Journal:  J Int Med Res       Date:  1992-11       Impact factor: 1.671

Review 9.  Probable vancomycin-induced neutropenia.

Authors:  Marisel Segarra-Newnham; Shari S Tagoff
Journal:  Ann Pharmacother       Date:  2004-10-05       Impact factor: 3.154

10.  Aztreonam-induced myelosuppression during treatment of Pseudomonas aeruginosa pneumonia.

Authors:  M M Dallal; J S Czachor
Journal:  DICP       Date:  1991-06
View more
  2 in total

1.  Renal replacement therapy and concurrent fluconazole therapy increase linezolid-related thrombocytopenia among adult patients.

Authors:  Yueh-Chun Hsu; Szu-Ying Chen; Yung-Jun Hung; Yu-Wei Huang
Journal:  Sci Rep       Date:  2022-06-14       Impact factor: 4.996

2.  Staphylococcus lugdunensis Urinary Tract Infection With Associated Neutropenic Fever.

Authors:  Rajanish Bobde; Joseph I Berger; Urma Jalil; Garine Kalaydjian
Journal:  Cureus       Date:  2022-01-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.